序号 |
标题 |
次数 |
作者 |
发布时间 |
74656 |
Galβ1-3GlcNAcβ1-3Gal-O-(CH2)3-NH2.HCl |
80 |
zyl |
2024-12-18 |
74657 |
DOTA-PEG4-LLP2A |
103 |
h |
2024-12-18 |
74658 |
cas:70396-18-8 , Boc-Val-Ala-OH,(S)-2-((S)-2-((叔丁氧基羰基)氨基)-3-甲基丁酰胺基)丙酸 |
84 |
kx |
2024-12-18 |
74659 |
cas:1127247-34-0,2,5-Dioxopyrrolidin-1-yl 3-(2-methoxyethoxy)propanoate |
86 |
wyh |
2024-12-18 |
74660 |
Glcα1-4Glc-O-(CH2)3-NH-Biotin 麦芽糖DP2与生物素连接(接头-BT B)-科研定制 |
131 |
zyl |
2024-12-18 |
74661 |
cas:150114-97-9 ,Fmoc-Val-Ala-OH,Fmoc-L-缬氨酰-L-丙氨酸 |
89 |
kx |
2024-12-18 |
74662 |
E{E[c(RGDyK)]缀合大环螯合剂NOTA NOTA-E{E[c(RGDyK)] |
99 |
h |
2024-12-18 |
74663 |
Mal-amido-PEG8-Val-Gly (CAS: 2353409-54-6) |
157 |
WYQ |
2024-12-18 |
74664 |
(4E)-TCO-C3-PEG3-C3-amine |
73 |
zyl |
2024-12-18 |
74665 |
Fmoc-Ala-Pro-OH (CAS: 186023-44-9) |
149 |
WYQ |
2024-12-18 |
74666 |
BTP-7肽和细胞穿膜肽BR2共修饰的吲哚菁绿-米托蒽醌脂质体,BTP-7/BR2-ICG/MTO-LP |
108 |
axc |
2024-12-18 |
74667 |
Fmoc-PEG4-Val-Ala-PAB-PNP,N-芴甲氧羰基-四聚乙二醇-VAL-ALA-PAB-PNP |
72 |
kx |
2024-12-18 |
74668 |
Azide-PEG12-CH2CH2CH2-COOtBu |
68 |
zyl |
2024-12-18 |
74669 |
GNR-DOX-cRGD 阿霉素和cRGD共轭的金纳米棒 |
93 |
h |
2024-12-18 |
74670 |
Boc-Val-Cit-PAB-PNB(CAS:870487-10-8) |
97 |
WYQ |
2024-12-18 |
74671 |
MC (C5)-Val-Cit,CAS号:2504147-59-3 |
70 |
WYQ |
2024-12-18 |
74672 |
5-FAM-C3-SH |
137 |
zyl |
2024-12-18 |
74673 |
NOTA-gg Nle-CycMSHhex {(67)Ga-1,4,4DOTA-GGNle-CycMSHhex |
90 |
h |
2024-12-18 |
74674 |
cas:2353409-54-6 ,Mal-amido-PEG8-Val-Gly,马来酰亚胺-酰胺-八聚乙二醇-VAL-GLY |
117 |
kx |
2024-12-18 |
74675 |
MC-Val-Cit-PAB-OH(CAS:159857-80-4) |
116 |
WYQ |
2024-12-18 |
74676 |
叶酸靶向BQR-SS-DOX脂质体前药,BQR-SS-DOX/DSPE-PEG2000-FA,靶向脂质体定制服务 |
78 |
axc |
2024-12-18 |
74677 |
N3-C4-NHS ester,478801-48-8 |
82 |
zyl |
2024-12-18 |
74678 |
NOTA-GO 螯合剂NOTA偶联纳米石墨烯 |
103 |
h |
2024-12-18 |
74679 |
Fmoc-Ala-Ser(Psi(Me,Me)pro)-OH CAS:252554-78-2 |
70 |
WYQ |
2024-12-18 |
74680 |
CAS:863971-53-3,Fmoc-Val-Cit-PAB-PNP,抗体药物偶联物FMOC-VAL-CIT-PAB-PNP |
100 |
kx |
2024-12-18 |
74681 |
Cl-C6-PEG12-NHCO-C3-NHS,2727166-23-4烷基链 |
98 |
zyl |
2024-12-18 |
74682 |
PD-L1单抗修饰的尼洛替尼脂质体,LP-Nilotinib/αPDL1,αPDL1修饰的Nilotinib脂质体 |
118 |
axc |
2024-12-18 |
74683 |
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB CAS:2055042-69-6 |
80 |
WYQ |
2024-12-18 |
74684 |
Cl-C6-PEG9-NH2 hydrochloride-烷基链 |
71 |
zyl |
2024-12-18 |
74685 |
Fmoc-Val-Cit-PAB-OH CAS:159858-22-7 |
75 |
WYQ |
2024-12-18 |
74686 |
CAS:159857-80-4,MC-Val-Cit-PAB-OH ,MC-VAL-CIT-PAB中间体 |
69 |
kx |
2024-12-18 |
74687 |
Biotin-C6-amine,65953-56-2烷基链试剂 |
89 |
zyl |
2024-12-18 |
74688 |
鹿茸多肽脂质体水凝胶,Velvet,antler,peptides,liposome,hydrogel,VAP-Lip-Gel,脂质体纳米载体定制服务 |
96 |
axc |
2024-12-18 |
74689 |
NOTA-Bn-SCN-Aoc-BN(7-14)S-2-(4-异硫氰基苄基)-NOTA偶联BN(7-14) |
86 |
h |
2024-12-18 |
74690 |
CAS:2055048-57-0,Fmoc-PEG4-Ala-Ala-Asn-PAB ,芴甲氧羰基-四聚乙二醇-ALA-ALA ASN-PAB |
76 |
kx |
2024-12-18 |
74691 |
NH2-PEG3-C6-Cl,1261350-60-0 |
69 |
zyl |
2024-12-18 |
74692 |
MC-Val-Cit-PAB-PNP(CAS:159857-81-5) |
95 |
WYQ |
2024-12-18 |
74693 |
NOTA-HSA 大环配体NOTA偶联人血清白蛋白 |
71 |
h |
2024-12-18 |
74694 |
SPDP-Val-Cit-PAB-OH(N-琥珀酰亚胺基-3-(2-吡啶二硫)丙酸) |
57 |
WYQ |
2024-12-18 |
74695 |
鹿茸多肽脂质体,Velvet,antler,peptides,liposome,VAP-Lip,多功能载药脂质体定制服务 |
109 |
axc |
2024-12-18 |
74696 |
NOTA-西妥昔单抗-800CW NOTA-cetuximab-800CW |
66 |
h |
2024-12-18 |
74697 |
CAS:644981-35-1,Val-Cit-PAB-MMAE , ADC试剂 |
62 |
kx |
2024-12-18 |
74698 |
SPDP-Val-Cit-PAB-PNP,分子式:C33H39N7O9S2 |
81 |
WYQ |
2024-12-18 |
74699 |
Azido-PEG4-Ala-Ala-Asn(Trt)-PAB(CAS:2055042-67-4) |
130 |
WYQ |
2024-12-18 |
74700 |
负载黄芩苷脂质体的纳米纤维膜,BCL-LPs/PVA-CS,NFs,载药脂质体定制服务 |
129 |
axc |
2024-12-18 |